Pfizer Inc.

Address: 66 Hudson Boulevard East

Sponsor Overview

assignment

162

Specializations

Oncology and Hematologic Malignancies

Breast cancer, non-small cell lung cancer, small cell lung cancer, prostate cancer, and colorectal cancer are central areas of interest, alongside studies in ovarian cancer, head and neck squamous cell carcinoma, esophageal cancer, hepatocellular carcinoma, and bladder cancer. Research also extends to blood cancers such as multiple myeloma, diffuse large B-cell lymphoma, follicular lymphoma, acute lymphoblastic leukemia, and advanced lymphomas.

HER2-negative and hormone receptor-positive breast cancer
Advanced solid tumors
Relapsed or refractory multiple myeloma
Diffuse large B-cell lymphoma
Metastatic castration-resistant prostate cancer

Additional oncology work includes melanoma, non-muscle invasive bladder cancer, liposarcoma, and neuroblastoma, with a strong emphasis on advanced and metastatic disease settings.

Inflammatory and Autoimmune Disorders

Clinical research spans rheumatoid arthritis, systemic lupus erythematosus, cutaneous lupus erythematosus, idiopathic inflammatory myopathies, and juvenile idiopathic arthritis. The portfolio also includes immune-mediated skin and bowel diseases such as atopic dermatitis, alopecia areata, vitiligo, ulcerative colitis, Crohn’s disease, and eosinophilic esophagitis.

Atopic dermatitis
Vitiligo
Ulcerative colitis
Rheumatoid arthritis
Systemic lupus erythematosus

Other immune-focused studies address chronic spontaneous urticaria, hidradenitis suppurativa, and immune-mediated inflammatory disorders affecting skin, joints, and gastrointestinal tissues.

Hematology, Bleeding Disorders, and Cardiovascular Disease

Key hematology programs involve hemophilia A, hemophilia B, and primary immune thrombocytopenia, with attention to inherited bleeding disorders across pediatric and adult populations. Cardiovascular research includes heart failure, heart failure with preserved ejection fraction, and pulmonary arterial hypertension.

Hemophilia A
Hemophilia B
Primary immune thrombocytopenia
Heart failure with preserved ejection fraction
Pulmonary arterial hypertension

Additional areas include transthyretin amyloidosis and transthyretin amyloid cardiomyopathy, reflecting interest in rare cardiovascular and systemic protein-aggregation disorders.

Infectious Diseases and Vaccines

Pfizer’s infectious disease portfolio includes studies in COVID-19, RSV infection, pneumococcal infections, group B streptococcus disease, and serious gram-negative bacterial infections. Research also covers hospital-acquired pneumonia, ventilator-associated pneumonia, sepsis, and complicated urinary tract infection.

Respiratory syncytial virus
Group B streptococcus
Pneumococcal disease
Gram-negative bacterial infections
COVID-19

Vaccine-oriented work includes maternal and infant immunization studies, with emphasis on neonatal protection and prevention of invasive bacterial and respiratory infections.

Neurology, Metabolic, and Other Therapeutic Areas

Neurology studies focus on migraine, including chronic migraine, menstrual migraine, and migraine with or without aura, as well as prevention in adolescents. Metabolic and supportive-care research includes obesity, overweight management, type 2 diabetes mellitus, and cancer cachexia.

Migraine disorders
Obesity and overweight management
Type 2 diabetes mellitus
Cancer cachexia
Growth hormone deficiency

Other areas of interest include duchenne muscular dystrophy, IgA nephropathy, obesity-related appetite loss, and erosive esophagitis, showing breadth across neuromuscular, renal, gastrointestinal, and metabolic conditions.

Sponsored Trials

Trial Name	Country	Status
A Bioequivalence and Safety Study of Free Acid Tafamidis 61 mg Capsule and Tablet in Healthy Adults Under Fed Conditions for the Treatment of Transthyretin Amyloidosis	Belgium	Not Recruiting
A Comparative Bioavailability and Bioequivalence Study of Two Dosage Formulations of an Investigational Medicinal Product in Healthy Adults for Migraine Management	Belgium	Not Recruiting
A Pharmacokinetic Study of Ibuzatrelvir Following Oral Administration in Healthy Adults	Belgium	Not Recruiting
A Phase 1 Study to Evaluate the Safety and Pharmacokinetics of PF-08046876 in Participants with Advanced Solid Tumors	Spain	Recruiting
A Phase 1 Study to Evaluate the Safety and Pharmacokinetics of PF-08052667 in Patients with Non-Muscle Invasive Bladder Cancer (NMIBC)	France Spain	Recruiting
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Ritlecitinib in Adults with Moderate to Severe Hidradenitis Suppurativa	Germany Greece Poland Spain	Not Recruiting
A Phase 2b Randomized, Double-Blind Study to Evaluate the Efficacy and Safety of Ritlecitinib in Adult Participants with Chronic Spontaneous Urticaria	Bulgaria Germany Poland Spain	Recruiting
A Phase I Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of PF-08065010 in Healthy Adults	Belgium	Recruiting
A Randomized, Double‑Blind, Placebo‑Controlled Phase 2/3 Study of Subcutaneous PF‑07275315 in Adults with Moderate‑to‑Severe Chronic Obstructive Pulmonary Disease	Bulgaria Czechia France Germany Greece Hungary Italy Poland Spain	Not Yet Recruiting
B7841007 - An Open-Label Extension Study to Evaluate the Long-Term Safety, Tolerability, and Efficacy of Marstacimab Prophylaxis in Severe (Coagulation Factor Activity <1%) Hemophilia A Participants With or Without Inhibitors or Moderately Severe to Severe Hemophilia B Participants (Coagulation Factor Activity ≤2%) With or Without Inhibitors	Austria Croatia Czechia Denmark France Germany Italy Slovakia Spain	Recruiting